TuHURA Biosciences (HURA) to Release Quarterly Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) is anticipated to release its results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07).

TuHURA Biosciences Stock Performance

TuHURA Biosciences stock opened at $2.38 on Wednesday. The firm has a market cap of $121.99 million and a price-to-earnings ratio of -1.38. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.20. The firm has a 50 day moving average price of $2.47 and a two-hundred day moving average price of $2.76.

Hedge Funds Weigh In On TuHURA Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new stake in TuHURA Biosciences in the 2nd quarter valued at about $27,000. Invesco Ltd. acquired a new stake in TuHURA Biosciences in the second quarter valued at approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $31,000. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences during the fourth quarter valued at approximately $59,000. Finally, Jane Street Group LLC acquired a new position in shares of TuHURA Biosciences during the first quarter worth approximately $69,000. Institutional investors own 0.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HURA. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Wall Street Zen raised TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, TuHURA Biosciences has an average rating of “Buy” and a consensus target price of $11.50.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.